The value of Neutrophils to Lymphocytes ratio and Platelets to Lymphocytes ratio as a prognostic factor for post-neoadjuvant chemotherapy residual disease in advanced ovarian cancer | ||||
| ARCADEs of MEDICINE | ||||
| Articles in Press, Accepted Manuscript, Available Online from 06 July 2025 | ||||
| Document Type: Original Research | ||||
| DOI: 10.21608/arcmed.2025.357721.1089 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Ola M Elfarargy 1; Noha Rashad 2; Mona M Mamdouh3; Fady A Shaban  4
| ||||
| 11-Department of Medical Oncology, Armed Forces College of Medicine, Cairo, Egypt 2-Department of Medical Oncology, Faculty of Medicine, Zagazig university, Zagazig, Egypt | ||||
| 21-Department of Clinical Oncology, Faculty of Medicine, Suez University, Suez, Egypt 2-Medical Oncology Department, Armed Forces College of Medicine, Cairo, Egypt | ||||
| 3Department of Pathology, National Cancer Institute, Cairo University, Cairo, Egypt | ||||
| 4Department of Medical Oncology, Armed Forces College of Medicine, Cairo, Egypt | ||||
| Abstract | ||||
| Background: Ovarian cancer is a common gynecological malignancy diagnosed at advanced stages, often requiring neoadjuvant chemotherapy followed by interval debulking surgery. Inflammatory biomarkers, such as NLR and PLR, are used to predict treatment response. Methodology: This prospective cohort study included 72 patients diagnosed with advanced ovarian cancer. Baseline laboratory measurements were taken before administering neoadjuvant chemotherapy, followed by interval debulking surgery. Hemoglobin, platelet count, total leucocyte count, NLR, and PLR were measured. NLR was calculated by dividing the absolute neutrophil count by the lymphocyte count, and PLR was calculated by dividing the platelet count by the lymphocyte count. The radiological response was assessed using CT scans and RECIST criteria, while the chemotherapy response score (CRS) was evaluated on surgical specimens. Results: Patients were grouped based on baseline NLR and PLR cut-off values. CRS3 was achieved more frequently among the groups in the low NLR group (31.3% vs. 15.0%), but without statistical significance (p=0.153). Baseline low PLR and high PLR groups achieved similar CRS3 levels (20.5% vs. 24.2%, p=0.882). For radiological remission, high baseline NLR and PLR were associated with a more complete response (CR), but differences were statistically insignificant. Conclusion: The baseline high NLR group showed more patients with pathological response CRS2 and more patients with less radiological residual post neoadjuvant chemotherapy in advanced ovarian cancer but they were statistically insignificant. Baseline PLR didn’t show any statistical differences. | ||||
| Keywords | ||||
| Chemotherapy response score; Neoadjuvant chemotherapy; NLR; PLR; and Prognosis | ||||
|
Statistics Article View: 58 |
||||
